Challenges with advanced therapy medicinal products and how to meet them

• Published in: Nature reviews. Drug discovery Vol. 9; no. 3; pp. 195 - 201
• Main Authors: Schneider, Christian K, Salmikangas, Paula, Jilma, Bernd, Flamion, Bruno, Todorova, Lyubina Racheva, Paphitou, Anna, Haunerova, Ivana, Maimets, Toivo, Trouvin, Jean-Hugues, Flory, Egbert, Tsiftsoglou, Asterios, Sarkadi, Balázs, Gudmundsson, Kolbeinn, O'Donovan, Maura, Migliaccio, Giovanni, Ancāns, Jānis, Maciulaitis, Romaldas, Robert, Jean-Louis, Samuel, Anthony, Ovelgönne, Johannes H, Hystad, Marit, Fal, Andrzej Mariusz, Lima, Beatriz Silva, Moraru, Anca Stela, Turcáni, Peter, Zorec, Robert, Ruiz, Sol, Akerblom, Lennart, Narayanan, Gopalan, Kent, Alastair, Bignami, Fabrizia, Dickson, J George, Niederwieser, Dietger, Figuerola-Santos, María-Angeles, Reischl, Ilona G, Beuneu, Claire, Georgiev, Rosen, Vassiliou, Maria, Pychova, Alena, Clausen, Mette, Methuen, Taina, Lucas, Sophie, Schüssler-Lenz, Martina, Kokkas, Vasilios, Buzás, Zsuzsanna, MacAleenan, Niall, Galli, Maria Cristina, Linē, Aija, Gulbinovic, Jolanta, Berchem, Guy, Fraczek, Mariusz, Menezes-Ferreira, Margarida, Vilceanu, Nela, Hrubisko, Mikulás, Marinko, Petra, Timón, Marcos, Cheng, Wing, Crosbie, George Andrew, Meade, Nick, di Paola, Michelino Lipucci, VandenDriessche, Thierry, Ljungman, Per, D'Apote, Lucia, Oliver-Diaz, Olga, Büttel, Isabel, Celis, Patrick
• Format: Journal Article Book Review
• Language: English
• Published: London Nature Publishing Group UK 01.03.2010; Nature Publishing Group
• Subjects: 631/154/155; 631/154/51/1844; 631/154/51/201; 631/61/2035; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cancer; Cancer Research; Care and treatment; European Union; Genetic Therapy - legislation & jurisprudence; Genetic Therapy - methods; Government Regulation; Humans; Medicinal Chemistry; Molecular Medicine; opinion-2; Pharmacology/Toxicology; Stem Cell Transplantation - legislation & jurisprudence; Stem Cell Transplantation - methods; Tissue Engineering - legislation & jurisprudence; Europe
• ISSN: 1474-1776; 1474-1784
• DOI: 10.1038/nrd3052

Advanced therapy medicinal products (ATMPs) offer hope for the treatment of diseases for which therapeutic options are currently lacking. This article discusses the regulatory role of the Committee for Advanced Therapies at the European Medicines Agency, highlighting issues and challenges observed in ATMP development. Advanced therapy medicinal products (ATMPs), which include gene therapy medicinal products, somatic cell therapy medicinal products and tissue-engineered products, are at the cutting edge of innovation and offer a major hope for various diseases for which there are limited or no therapeutic options. They have therefore been subject to considerable interest and debate. Following the European regulation on ATMPs, a consolidated regulatory framework for these innovative medicines has recently been established. Central to this framework is the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA), comprising a multidisciplinary scientific expert committee, representing all EU member states and European Free Trade Association countries, as well as patient and medical associations. In this article, the CAT discusses some of the typical issues raised by developers of ATMPs, and highlights the opportunities for such companies and research groups to approach the EMA and the CAT as a regulatory advisor during development.